(Q34856849)

4 August 2017

Switching first-line disease-modifying therapy after failure: impact on the course of relapsing-remitting multiple sclerosis (English)

1 reference

relapsing-remitting multiple sclerosis

4 August 2017

0 references

0 references

A Gajofatto

1

0 references

Emmanuelle Waubant

series ordinal

5

object named as

E Waubant

1 reference

4 August 2017

P Bacchetti

2

1 reference

PubMed ID

18922831

4 August 2017

B Grimes

series ordinal

3

1 reference

PubMed ID

18922831

4 August 2017

A High

series ordinal

4

1 reference

4 August 2017

15 October 2008

1 reference

Multiple Sclerosis Journal

4 August 2017

1 reference

4 August 2017

15

1 reference

4 August 2017

1

1 reference

4 August 2017

50-58

1 reference

Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. II. MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial. UBC MS/MRI Study Group and the IFNB Multiple Sclerosis Study Group

4 August 2017

1 reference

https://api.crossref.org/works/10.1177%2F1352458508096687

Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458508096687

Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG)

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458508096687

Magnetic resonance studies of intramuscular interferon beta-1a for relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458508096687

Clinical characteristics of responders to interferon therapy for relapsing MS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458508096687

Defining interferon beta response status in multiple sclerosis patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458508096687

Clinical course after change of immunomodulating therapy in relapsing-remitting multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458508096687

Randomized, double-blind, dose-comparison study of glatiramer acetate in relapsing-remitting MS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458508096687

Every-other-day interferon beta-1b versus once-weekly interferon beta-1a for multiple sclerosis: results of a 2-year prospective randomised multicentre study (INCOMIN).

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458508096687

Pain and affective memory biases interact to predict depressive symptoms in multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458508096687

Effects of motor cortex rTMS on lower urinary tract dysfunction in multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458508096687

Quality Assessment in Multiple Sclerosis Therapy (QUASIMS): a comparison of interferon beta therapies for relapsing-remitting multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458508096687

Are initial demyelinating event recovery and time to second event under differential control?

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458508096687

New diagnostic criteria for multiple sclerosis: guidelines for research protocols

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458508096687

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458508096687

Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS)

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458508096687

Interrupted therapy: stopping and switching of the beta-interferons prescribed for MS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458508096687

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458508096687

Assessment of different treatment failure criteria in a cohort of relapsing-remitting multiple sclerosis patients treated with interferon β: Implications for clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458508096687

Defining the response to interferon-β in relapsing-remitting multiple sclerosis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458508096687

Randomised double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458508096687

21 January 2018

Identifiers

DOI

10.1177/1352458508096687

1 reference

4 August 2017

1 reference

PubMed ID

18922831